Nivalis Therapeutics, Inc.
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
Role: lead
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Role: lead
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
Role: lead
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
Role: lead
PK Study of N91115 in Cystic Fibrosis Patients
Role: lead
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
Role: lead
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
Role: lead
A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
Role: lead
Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Role: lead
Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
Role: lead
Safety and Tolerability Study of N6022 in Healthy Subjects
Role: lead
All 11 trials loaded